Qualifications of the Investigators.

BIOGRAPHICAL SKETCH

Provide the following information for the Principal Investigator and other key personnel

NAME: Amrollah Ahmadi

POSITION TITLE: Researcher

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as chemistry, and include postdoctoral training.)

As indicated by laboratory and experimental and human studies, HESA-A is the best alternative for prevention of cancer.

Yet, no such option has been proposed for prevention, so we suggest one week (14 tablets: 2 tablets daily) use of HESA-A each 6 months or two week each year. As the drug of HESA-A has no side effect or adverse effect; it is valuable way for human health.

RESEARCH AND PROFESSIONAL EXPERIENCE

FELLOWSHIPS/AWARDS

Fellowship in Anterior segment, 1992, Bores Eye Institute, Phoenix , USA .

AFFILIATIONS

Honor academic staff of Tehran University of Medical Sciences, Tehran, Iran

Honor academic staff of Shahed University, Tehran, Iran

PUBLICATIONS (relevant and last three years)

• Ahmadi A, Mohagheghi MA, Fazeli MS, Nahavandian B, Bashardoost N, Musavi Jarahi A, Gharipoor M. HESA-A: new treatment for breast cancer and choroidal metastasis.Med Sci Monit. 2005 Jun;11(6):CR300-303.
• Hojjat Sadeghi-Aliabadi, Amrollah Ahmadi. “Cytotoxicity and Antitumor Properties of a Marine Compound , HESA-A, on Cancer Cells”. DARU, Tehran University of Medical Sciences.11(3):82-87, 2003.
• Ahmadi A, Naderi G, Asgary S. Evaluation of hepatoprotective potential of HESA-A (a marine compound) pretreatment against thioacetamide-induced hepatic damage in rabbits. Drugs Exp Clin Res. 2005;31(1):1-6.
• Valiollah Hajhashemi, Taghi Ghafghazi, Mehdi Balali, Amrollah Ahmadi, Mashollah Taher, Parvin Rajabi, Ardeshir Talebi. “Toxicological Studies on an Anticancer Drug,(HESA-A) with Marine Origin”. Medical Journal of Islamic Academy of Sciences , 14:4, 145-149, 2001.
• Hajhashemi V, Ghafghazi T, Ahmadi A. Study the Sub-Acute Toxicity of Natural Product MS14 in Rat. Daneshvar Medicine 2004; 11(52): 11-14.
• Ballali M, Ahmadi A, Ballali K, Ghfghazi T, Rajabi P, Taher M. Toxicity evaluation of an antitumor marin compound (HRSA-A) in mice and rats. Journal of Birjand University of Medical Sciences, 2005;23 (1,2):5-12
• Ahmadi A, et al. MS14 halts progressiveness of the disease in experimental allergic encephalomyelitis. Phytotherapy Res, (accepted), In press
• Naseri M, Ahmadi A, Ghareghozli K, et al. Clinical and toxicological evaluation of MS14 natural product in patients with multiple sclerosis. Daneshvar Medicine 2007; 14 (68): 59-65 (in Persian)
• Ahmadi A, et al. The effect of HESA-A on Psoriasis vulgaris: a randomized double blind controlled clinical trial. In press
• Ahmadi A, et al. Therapeutic Effect of HESA-A in Age Related Macular Degeneration: A Randomized Double Blind Controlled Clinical Trial. In press.
• Ahmadi A, et al. The Effect of HESA-A, an herbal-marine medicine, on Wound Healing Process in an incisional wound healing model: An Experimental Study. In press

Conferences

Bibi Sedigheh Fazly Bazzaz, Jalil Tavakoli Afshar, Amrollah Ahmadi, Zahra Sabeti, Behnaz Safei. “HESA- A, Its Cytotoxicity and Mutagenicity”. 12th International Congress of Immunology (ICI) 2004, Montreal , Canada .

Ahmadi A. “Treatment of Non-Cardiogemic Plural Efugen by HESA-A Drug”. 7th Central European Lung Cancer Conference. Prague , Czech Republic , 2001.

Mohaghegh, A. Ahmadi, M. Taher, N. Bashardoost, B. Nahavandian, M. Karimi, A.R. Moosavi Jarrahi. “A Study of the Anticancer Effects of HESA-A in Patients with Metastatic Liver Cancer”. 3rd International Congress of health, Environment & Natural Products, Mashhad University of Medical Sciences, 2004, Mashhad.

Ahmadi et al. Introduction of therapeutic effectiveness of HESA-A on induced osteosarcoma in rabit. The first Iranian congress of Cancer Research, 15 May 2001Uromyyeh, Iran.

Ahmadi et al. Study of chronic toxicity of HESA-A in Sori and rat. First Iranian congress of Cancer Research. 15 May 2001Uromyyeh, Iran